Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman
10 Julio 2024 - 10:50AM
Business Wire
Expansion of the Board and the company’s
recent FDA Clearance marks the beginning of Orthobond’s
commercialization phase
Orthobond Corporation, a leader in covalently-bound
antibacterial surface technologies with broad applications in the
medical device industry, today publicly announced the appointment
of Eric Major as the company’s Chairman of the Board.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240710922166/en/
Eric Major (Photo: Business Wire)
"We are pleased to be expanding Orthobond’s Board of Directors
with the appointment of Eric, whose vast experience in the medical
device space and in driving strategic growth will be an
instrumental part of Orthobond’s future,” said David Nichols, CEO
of Orthobond. “The timing of Eric’s appointment is ideal given our
recent announcement of our FDA clearance of the first
anti-bacterial non-drug eluting solution.”
Mr. Major has over 30 years of industry experience and has a
distinguished career as an entrepreneur, CEO, and Chairman. He
currently serves as the Executive Chairman of the Board at
Highridge Medical. His extensive background spans startup and
early-stage funding, Venture Capital, Private Equity, and IPOs. His
expertise extends to managing public companies, steering both
public and private board governance, overseeing global operations,
and formulating strategies for M&A and business integration. In
his previous role as President of Stryker Spine, Mr. Major
successfully led the merger of Stryker Spine’s legacy operations
with K2M and growth performance. As a founder of K2M, he also held
the positions of Chairman, President, and CEO, from a start-up to a
publicly traded global franchise.
“Eric’s impressive career, spanning over three decades in the
industry, is a testament to his extensive expertise and visionary
leadership,” said Frank Cammisa, MD, Chief Emeritus of HSS Spine at
Hospital for Special Surgery, CMO and Board Member at Orthobond.
“His arrival marks a new chapter of innovation and growth for our
company and we are thrilled to welcome such an experienced leader
to help lead us toward a brighter future for Orthobond.”
“Orthobond’s antibacterial technology is a true breakthrough for
patient care in the medical device space and the recent FDA
clearance allows for a new and exciting chapter for the company,”
said Major. “I am thrilled to be joining Orthobond at such a
pivotal time. I look forward to working with an impressive Board of
Directors and operating team as we enter the commercial phase for
this revolutionary technology.”
Major’s addition underscores the Orthobond Board and management
team’s dedication to hiring and leveraging top-tier executive and
operational expertise at every level. Backed by Point72 Ventures,
Orthobond has been able to establish a talented and knowledgeable
board that ensures exceptional research and innovative design
remain at the forefront of the company’s mission.
About Orthobond
Orthobond Corporation is a surface technology company that has
developed proprietary antibacterial surfaces with broad
applications in multiple industries such as medical device,
commercial, industrial, automotive, and beyond. Orthobond is the
first company to utilize surface modifications that can be
permanently bound to any surface, killing bacteria by mechanically
rupturing pathogens without using eluting antibiotics.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240710922166/en/
Media Sean Leous ICR Westwicke Sean.Leous@Westwick.com
646-866-4012